<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="pmcid: 5573746 doi: 10.3345/kjp.2017.60.7.227 : Original Article Effects of low-dose" exact="topiramate" post="on language function in children with migraine Han Seung-A"/>
 <result pre="Purpose This study aimed to verify the safety of low-dose" exact="topiramate" post="on language development in pediatric patients with migraine. Methods"/>
 <result pre="Methods Thirty newly diagnosed pediatric patients with migraine who needed" exact="topiramate" post="were enrolled and assessed twice with standard language tests,"/>
 <result pre="computerized speech laboratory analysis. Data were collected before treatment, and" exact="topiramate" post="as monotherapy was sustained for at least 3 months."/>
 <result pre="months. The mean follow-up period was 4.3±2.7 months. The mean" exact="topiramate" post="dosage was 0.9 mg/kg/day. Results The patient's mean age"/>
 <result pre="parameters of the TOPs were not changed significantly after the" exact="topiramate" post="treatment as follows: Determine cause, from 15.0±4.4 to 15.4±4.8"/>
 <result pre="the patients; however, the number of vocabularies used decreased. Therefore," exact="topiramate" post="should be used cautiously for children with migraine. Child"/>
 <result pre="prescribed for migraine prophylaxis. Among these drugs, antiepileptic drugs, especially" exact="topiramate" post="(TPM), are most frequently prescribed for children and adolescents."/>
 <result pre="Schmidt D Reid S et al. Double-blind, placebo-controlled trial of" exact="topiramate" post="as add-on therapy in patients with refractory partial seizures"/>
 <result pre="Reife R Pledger G et al. Double-blind, placebo-controlled study of" exact="topiramate" post="in patients with refractory partial epilepsy Epilepsy Res 1996"/>
 <result pre="Shorvon S Henriksen O et al. Double-blind, placebo-controlled trial of" exact="topiramate" post="(600 mg daily) for the treatment of refractory partial"/>
 <result pre="Elger CE Helmstaedter C Efficacy and cognitive side effects of" exact="tiagabine" post="and topiramate in patients with epilepsy Epilepsy Behav 2005"/>
 <result pre="Helmstaedter C Efficacy and cognitive side effects of tiagabine and" exact="topiramate" post="in patients with epilepsy Epilepsy Behav 2005 6 373"/>
 <result pre="X Lui S et al. Altered cerebral activity associated with" exact="topiramate" post="and its withdrawal in patients with epilepsy with language"/>
 <result pre="Kim SJ Kim MY Choi YM Song MK Effects of" exact="topiramate" post="on language functions in newly diagnosed pediatric epileptic patients"/>
 <result pre="41 968 975 11903524 18 Brandes JL Practical use of" exact="topiramate" post="for migraine prevention Headache 2005 45 Suppl 1 S66"/>
 <result pre="S Shajari A Fromandi M The efficacy and safety of" exact="topiramate" post="for prophylaxis of migraine in children Iran J Child"/>
 <result pre="F Zakizade N Nasr V Comparison of the effect of" exact="topiramate" post="and sodium valporate in migraine prevention: a randomized blinded"/>
 <result pre="KL Ding M Eberly LE et al. The effect of" exact="topiramate" post="plasma concentration on linguistic behavior, verbal recall and working"/>
 <result pre="T Carmo I et al. Cognitive effects of therapy with" exact="topiramate" post="in patients with refractory partial epilepsy Rev Neurol 2002"/>
 <result pre="Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with" exact="valproate" post="or topiramate Epilepsy Behav 2006 8 606 609 16504593"/>
 <result pre="of patients with juvenile myoclonic epilepsy treated with valproate or" exact="topiramate" post="Epilepsy Behav 2006 8 606 609 16504593 Table 1"/>
 <result pre="45.3±13.6 Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment. Table 2 The"/>
 <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment. Table 2 The total mean length of utterance"/>
 <result pre="* Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment. * P&amp;lt;0.05. Table"/>
 <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment. * P&amp;lt;0.05. Table 3 The results of the"/>
 <result pre="1,161.80±484.9 Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment; F1, formants 1;"/>
 <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment; F1, formants 1; F2, formants 2."/>
</results>
